<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">The reality is that a 5 year development program for a novel vaccine is fast. The only other novel vaccines approved by CBER in 2019, one for dengue fever (Dengvaxia, Sanofi) and one for smallpox and monkeypox (Jynneos, Bavarian Nordic), were both in clinical trials for approximately 15 years. Five-year clinical development is fast, even for drugs, and generally limited to ground-breaking precision medicines for indications with unmet medical need where the FDAâ€™s Centre for Drug Evaluation and Research works intensively with drug developers to impart their knowledge and expertise, built over decades and across thousands of new drug development programs [
 <xref rid="bb0040" ref-type="bibr">8</xref>,
 <xref rid="bb0045" ref-type="bibr">9</xref>].
</p>
